Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G., Kammerer, Sarah, Chandrupatla, Durga M.S.H., Honeywell, Richard, Musters, Rene P.J., Giovannetti, Elisa, O'Toole, Tom, Scheffer, George L., Krige, David, de Gruijl, Tanja D., Niessen, Hans W.M., Lems, Willem F., Kramer, Pieternella A., Scheper, Rik J., Cloos, Jacqueline, Ossenkoppele, Gert J., Peters, Godefridus J., Jansen, Gerrit
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868683/
https://ncbi.nlm.nih.gov/pubmed/26496029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6169
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items